Merck KGaA says ‘no certainty’ SpringWorks deal will be signed

Merck KGaA (MKGAY) said in its annual report this morning: “On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics (SWTX), Inc., USA. At the time of the preparation of the Consolidated Financial Statements, there existed no certainty that a merger agreement would be signed.” Barclays this morning pointed out that SpringWorks cancelled this morning from its conference next week, following cancellations from other public events since the neurofibromatosis type one approval on February 11. Shares of SpringWorks are down 19c to $50.40 in premarket trading.